Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care?
OBJECTIVES: With the development of next-generation sequencing (NGS) technologies, DNA sequencing has been increasingly utilized in clinical practice. Our goal was to investigate the impact of genomic evaluation on treatment decisions for heavily pretreated patients with metastatic cancer. METHODS:...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier España
|
| Series: | Clinics |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322017001000588&lng=en&tlng=en |
| _version_ | 1811327474209914880 |
|---|---|
| author | Gustavo S. Fernandes Daniel F. Marques Daniel M. Girardi Maria Ignez F. Braghiroli Renata A. Coudry Sibele I. Meireles Artur Katz Paulo M. Hoff |
| author_facet | Gustavo S. Fernandes Daniel F. Marques Daniel M. Girardi Maria Ignez F. Braghiroli Renata A. Coudry Sibele I. Meireles Artur Katz Paulo M. Hoff |
| author_sort | Gustavo S. Fernandes |
| collection | DOAJ |
| description | OBJECTIVES: With the development of next-generation sequencing (NGS) technologies, DNA sequencing has been increasingly utilized in clinical practice. Our goal was to investigate the impact of genomic evaluation on treatment decisions for heavily pretreated patients with metastatic cancer. METHODS: We analyzed metastatic cancer patients from a single institution whose cancers had progressed after all available standard-of-care therapies and whose tumors underwent next-generation sequencing analysis. We determined the percentage of patients who received any therapy directed by the test, and its efficacy. RESULTS: From July 2013 to December 2015, 185 consecutive patients were tested using a commercially available next-generation sequencing-based test, and 157 patients were eligible. Sixty-six patients (42.0%) were female, and 91 (58.0%) were male. The mean age at diagnosis was 52.2 years, and the mean number of pre-test lines of systemic treatment was 2.7. One hundred and seventy-seven patients (95.6%) had at least one identified gene alteration. Twenty-four patients (15.2%) underwent systemic treatment directed by the test result. Of these, one patient had a complete response, four (16.7%) had partial responses, two (8.3%) had stable disease, and 17 (70.8%) had disease progression as the best result. The median progression-free survival time with matched therapy was 1.6 months, and the median overall survival was 10 months. CONCLUSION: We identified a high prevalence of gene alterations using an next-generation sequencing test. Although some benefit was associated with the matched therapy, most of the patients had disease progression as the best response, indicating the limited biological potential and unclear clinical relevance of this practice. |
| first_indexed | 2024-04-13T15:08:31Z |
| format | Article |
| id | doaj.art-112b02f54ea548fbbd24de7147338e53 |
| institution | Directory Open Access Journal |
| issn | 1980-5322 |
| language | English |
| last_indexed | 2024-04-13T15:08:31Z |
| publisher | Elsevier España |
| record_format | Article |
| series | Clinics |
| spelling | doaj.art-112b02f54ea548fbbd24de7147338e532022-12-22T02:42:05ZengElsevier EspañaClinics1980-5322721058859410.6061/clinics/2017(10)01S1807-59322017001000588Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care?Gustavo S. FernandesDaniel F. MarquesDaniel M. GirardiMaria Ignez F. BraghiroliRenata A. CoudrySibele I. MeirelesArtur KatzPaulo M. HoffOBJECTIVES: With the development of next-generation sequencing (NGS) technologies, DNA sequencing has been increasingly utilized in clinical practice. Our goal was to investigate the impact of genomic evaluation on treatment decisions for heavily pretreated patients with metastatic cancer. METHODS: We analyzed metastatic cancer patients from a single institution whose cancers had progressed after all available standard-of-care therapies and whose tumors underwent next-generation sequencing analysis. We determined the percentage of patients who received any therapy directed by the test, and its efficacy. RESULTS: From July 2013 to December 2015, 185 consecutive patients were tested using a commercially available next-generation sequencing-based test, and 157 patients were eligible. Sixty-six patients (42.0%) were female, and 91 (58.0%) were male. The mean age at diagnosis was 52.2 years, and the mean number of pre-test lines of systemic treatment was 2.7. One hundred and seventy-seven patients (95.6%) had at least one identified gene alteration. Twenty-four patients (15.2%) underwent systemic treatment directed by the test result. Of these, one patient had a complete response, four (16.7%) had partial responses, two (8.3%) had stable disease, and 17 (70.8%) had disease progression as the best result. The median progression-free survival time with matched therapy was 1.6 months, and the median overall survival was 10 months. CONCLUSION: We identified a high prevalence of gene alterations using an next-generation sequencing test. Although some benefit was associated with the matched therapy, most of the patients had disease progression as the best response, indicating the limited biological potential and unclear clinical relevance of this practice.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322017001000588&lng=en&tlng=enMolecular ProfilingTargeted TherapyPrecisionRefractory |
| spellingShingle | Gustavo S. Fernandes Daniel F. Marques Daniel M. Girardi Maria Ignez F. Braghiroli Renata A. Coudry Sibele I. Meireles Artur Katz Paulo M. Hoff Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care? Clinics Molecular Profiling Targeted Therapy Precision Refractory |
| title | Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care? |
| title_full | Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care? |
| title_fullStr | Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care? |
| title_full_unstemmed | Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care? |
| title_short | Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care? |
| title_sort | next generation sequencing based genomic profiling fostering innovation in cancer care |
| topic | Molecular Profiling Targeted Therapy Precision Refractory |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322017001000588&lng=en&tlng=en |
| work_keys_str_mv | AT gustavosfernandes nextgenerationsequencingbasedgenomicprofilingfosteringinnovationincancercare AT danielfmarques nextgenerationsequencingbasedgenomicprofilingfosteringinnovationincancercare AT danielmgirardi nextgenerationsequencingbasedgenomicprofilingfosteringinnovationincancercare AT mariaignezfbraghiroli nextgenerationsequencingbasedgenomicprofilingfosteringinnovationincancercare AT renataacoudry nextgenerationsequencingbasedgenomicprofilingfosteringinnovationincancercare AT sibeleimeireles nextgenerationsequencingbasedgenomicprofilingfosteringinnovationincancercare AT arturkatz nextgenerationsequencingbasedgenomicprofilingfosteringinnovationincancercare AT paulomhoff nextgenerationsequencingbasedgenomicprofilingfosteringinnovationincancercare |